» Articles » PMID: 27294543

Affinity-controlled Protein Encapsulation into Sub-30 nm Telodendrimer Nanocarriers by Multivalent and Synergistic Interactions

Overview
Journal Biomaterials
Date 2016 Jun 14
PMID 27294543
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Novel nanocarriers are highly demanded for the delivery of heterogeneous protein therapeutics for disease treatments. Conventional nanoparticles for protein delivery are mostly based on the diffusion-limiting mechanisms, e.g., physical trapping and entanglement. We develop herein a novel linear-dendritic copolymer (named telodendrimer) nanocarrier for efficient protein delivery by affinitive coating. This affinity-controlled encapsulation strategy provides nanoformulations with a small particle size (<30 nm), superior loading capacity (>50% w/w) and maintained protein bioactivity. We integrate multivalent electrostatic and hydrophobic functionalities synergistically into the well-defined telodendrimer scaffold to fine-tune protein binding affinity and delivery properties. The ion strength and density of the charged groups as well as the structure of the hydrophobic segments are important and their combinations in telodendrimers are crucial for efficient protein encapsulation. We have conducted a series of studies to understand the mechanism and kinetic process of the protein loading and release, utilizing electrophoresis, isothermal titration calorimetry, Förster resonance energy transfer spectroscopy, bio-layer interferometry and computational methods. The optimized nanocarriers are able to deliver cell-impermeable therapeutic protein intracellularly to kill cancer cells efficiently. In vivo imaging studies revealed cargo proteins preferentially accumulate in subcutaneous tumors and retention of peptide therapeutics is improved in an orthotopic brain tumor, these properties are evidence of the improved pharmacokinetics and biodistributions of protein therapeutics delivered by telodendrimer nanoparticles. This study presents a bottom-up strategy to rationally design and fabricate versatile nanocarriers for encapsulation and delivery of proteins for numerous applications.

Citing Articles

Carbosilane Dendritic Amphiphiles from Cholesterol or Vitamin E for Micelle Formation.

Mencia G, Algar S, Lozano-Cruz T, Munoz-Fernandez M, Gillies E, Cano J Pharmaceutics. 2024; 16(4).

PMID: 38675112 PMC: 11053416. DOI: 10.3390/pharmaceutics16040451.


Engineering Nanotrap Hydrogel for Immune Modulation in Wound Healing.

Yang X, Guo D, Ji X, Shi C, Luo J Macromol Rapid Commun. 2023; 44(23):e2300322.

PMID: 37533180 PMC: 10834856. DOI: 10.1002/marc.202300322.


Functionalized core-shell nanogel scavenger for immune modulation therapy in sepsis.

Ji X, Yang X, Shi C, Guo D, Wang X, Messina J Adv Ther (Weinh). 2023; 5(10).

PMID: 36590645 PMC: 9797201. DOI: 10.1002/adtp.202200127.


Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders.

Lynch M, Gobbo O Nanomaterials (Basel). 2021; 11(10).

PMID: 34685073 PMC: 8538557. DOI: 10.3390/nano11102632.


A Rationally Designed Micellar Nanocarrier for the Delivery of Hydrophilic Methotrexate in Psoriasis Treatment.

Guo D, Shi C, Wang L, Ji X, Zhang S, Luo J ACS Appl Bio Mater. 2021; 3(8):4832-4846.

PMID: 34136761 PMC: 8204631. DOI: 10.1021/acsabm.0c00342.


References
1.
Sykes E, Chen J, Zheng G, Chan W . Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano. 2014; 8(6):5696-706. DOI: 10.1021/nn500299p. View

2.
Schmohl J, Todhunter D, Oh S, Vallera D . Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development. Toxins (Basel). 2015; 7(10):4067-82. PMC: 4626721. DOI: 10.3390/toxins7104067. View

3.
Vermonden T, Censi R, Hennink W . Hydrogels for protein delivery. Chem Rev. 2012; 112(5):2853-88. DOI: 10.1021/cr200157d. View

4.
Sizovs A, Song X, Waxham M, Jia Y, Feng F, Chen J . Precisely tunable engineering of sub-30 nm monodisperse oligonucleotide nanoparticles. J Am Chem Soc. 2013; 136(1):234-40. PMC: 3912943. DOI: 10.1021/ja408879b. View

5.
Mo R, Jiang T, Di J, Tai W, Gu Z . Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem Soc Rev. 2014; 43(10):3595-629. DOI: 10.1039/c3cs60436e. View